SERUM LACTATE-DEHYDROGENASE (LDH) AS A PROGNOSTIC INDEX FOR NON-HODGKINS LYMPHOMA
SERUM LACTATE-DEHYDROGENASE (LDH) AS A PROGNOSTIC INDEX FOR NON-HODGKINS LYMPHOMA
复制标题
DOI：
10.1016/0277-5379(82)90242-5
复制
发表时间：
1982-01-01
期刊：
影响因子：
--
通讯作者：
FOSSER, V
中科院分区：
文献类型：
--
作者：
ENDRIZZI, L;FIORENTINO, MV;FOSSER, V
根据血清乳酸脱氢酶（LDH）预处理值，将113例非霍奇金淋巴瘤患者分为3个水平：1级（正常范围内），LDH < 250 U/l；2级（中度升高），LDH在250 ~ 500 U/l之间；3级（高度增高），LDH浓度为500u /l。113例患者中有46例（41%）LDH升高。正常的LDH值与更好的治疗反应和更长的生存期相关，与组织学类型和临床分期无关，但有一个例外；在IV期患者中，无法得出关于治疗反应的结论（44例患者中只有8例完全缓解）。尽管2级患者的表现略好于3级患者，但在两个级别之间没有观察到统计学差异。因此，血清LDH可以被认为是非霍奇金淋巴瘤治疗反应和生存的有用预测因子。
According to pretreatment values of serum lactate dehydrogenase (LDH), 113 consecutive patients with non-Hodgkin''s lymphoma were divided into 3 levels: level 1 (within normal range) with LDH < 250 U/l; level 2 (moderately increased)with LDH between 250 and 500 U/l; level 3 (highly increased) with LDH > 500 U/l. LDH was elevated in 46 of 113 patients (41%). Normal values of LDH were associated with a better response to therapy and a longer survival, independent of histological type and clinical stage, with one exception; in stage IV patients conclusions could not be drawn concerning the response to therapy (complete remission occurred only in 8 of 44). Even though level 2 patients behaved slightly better than level 3 patients, no statistical difference has been observed between the two levels. Accordingly, serum LDH can be considered a useful predictor of response to therapy and of survival in non-Hodgkin''s lymphoma.